Helixor A enhances natural killer cell activity by induction of PAI-1 expression through the p38/MAPK signaling pathway.
Helixor A, an anticancer drug, has an immunostimulatory effect that increases T and natural killer (NK) cell activity in patients with cancer and endometriosis. However, the molecular mechanisms underlying its …